Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
LowReport
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Needham & Company LLC from $460.00 to $510.00. They now have a "buy" rating on the stock.
MediumReport
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Needham & Company LLC from $460.00 to $510.00. They now have a "buy" rating on the stock.
Praxis Precision Medicines (NASDAQ:PRAX) is now covered by analysts at Wells Fargo & Company. They set an "equal weight" rating and a $282.00 price target on the stock.
LowReport
Praxis Precision Medicines (NASDAQ:PRAX) is now covered by analysts at Wells Fargo & Company. They set an "equal weight" rating and a $282.00 price target on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: